New technologies for the identification of markers for early detection of ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 15, Issue 1, 2003, Pages 51-55

  Bandera, Christina A ^a   Ye, Bin ^a   Mok, Samuel C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biomarkers; Early detection; Microarray; Ovarian cancer; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; OSTEOPONTIN; PROSTASIN; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; DNA MICROARRAY; FEMALE; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CA-125 ANTIGEN; DNA, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MASS SCREENING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037306760     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200302000-00008     Document Type: Review

References (16)

1. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309:883-887.
2. Verheijen RH, von Mensdorff-Pouilly S, van Kamp GJ, Kenemans P. CA 125: fundamental and clinical aspects. Semin Cancer Biol 1999; 9:117-124.
3. Karlan BY, Baldwin RL, Lopez-Luevanos E, et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999; 180:917-928.
4. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353:1207-1210.
5. Woolas RP, Oram DH, Jeyarajah AR, et al. Ovarian cancer identified through screening with serum markers but not by pelvic imaging. Int J Gynecol Cancer 1999; 9:497-501.
6. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280:719-723.
7. Ismail RS, Baldwin RL, Fang J, et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res 2000; 60:6744-6749.
8. Matei D, Graeber TG, Baldwin RL, et al. Gene expression in epithelial ovarian carcinoma. Oncogene 2002; 21:6289-6298.
9. Shridhar V, Lee J, Pandita A, et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 2001; 61:5895-5904.
10. Sawiris GP, Sherman-Baust CA, Becker KG, et al. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res 2002; 62:2923-2928.
11. Manderson EN, Mes-Masson AM, Novak J, et al. Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Res 2002; 12:112-121.
12. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287:1671-1679. •• This paper describes the use of microarray technology to identify a potential ovarian cancer serum marker called osteopontin, and reports preliminary validation of its use for the early detection of the disease.
13. Mok SC, Chao J, Skates S, et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93:1458-1464. •• This paper describes the use of microarray technology to identify a potential ovarian cancer serum marker called prostasin, and reports preliminary validation studies of its use as a diagnostic tool.
14. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975; 250:4007-4021.
15. Alaiya AA, Franzen B, Hagman A, et al. Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. Int J Cancer 2002; 98:895-899.
16. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577. •• This paper describes the identification and validation of proteomic patterns for the detection of ovarian cancer.